女性健康| AbbVie新闻中心狗万平台活动

< ![CDATA[新联盟来解决多个痛点为女性患有子宫内膜异位症]]>

星期一,2020年11月16日05:39:00 EST

<强>华盛顿特区2020年11月16日,(美通社)< /强> mdash;今天,七women’ s health-focused组织mdash;< a href = " https://www.acog.org/ " >美国妇产科学院< / >(妇产科),< a href = " https://endometriosisassn.org/ " >的子宫内膜异位症协会< / >,< a href = " //www.worldcupnut.com/ " > AbbVie < / >、< a href = " https://www.healthywomen.org/womentalk/blog/real-women-real-stories-0 " > HealthyWomen < / >的< a href = " https://www.pelvicpain.org/ " target = "平等" >国际骨盆疼痛学会< / >(绿皮书),< a href = " https://www.gehealthcare.com/ " >通用电气医疗集团< / >和< a href = " https://bwhi.org/ " >黑色Women’健康必须< / > (BWHI) mdash;宣布成立的子宫内膜异位症联盟改善生活的10生殖年龄的女性患有这种疾病在美国。

< ![CDATA [FDA批准的第一个口服药物的管理重月经出血由于绝经前女性子宫肌瘤]]>

2020年5月29日星期五,16:05:00 EST

北芝加哥,病了。, May 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules), with a treatment duration of up to 24 months.² ORIAHNN is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.² ORIAHNN is expected to be available in the U.S. by the end of June 2020.

< ![CDATA[华纳齐克特和华生集体诉讼的解决反垄断的直接和间接购买者Loestrin 24铁和Minastrin 24 Fe]] >

星期一,2020年1月06 07:00:00 EST

<位置idsrc = " xmltag.org " value = "陆/ ie . .都柏林都柏林" > < /位置>,<时间> 1月。6, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island. The settlements make no admission of wrongdoing on the part of the company and resolve the litigation that was scheduled to go to trial on January 6, 2020.

< ![CDATA [AbbVie提交新药申请试用中的Elagolix美国食品及药物管理局管理的月经出血与子宫肌瘤女性]]>

妈,05年8月2019 08:08:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 8月。2019 & # 160;从AbbVie (NYSE: ABBV),全球生物制药公司研究,与神经内分泌的生物科学合作,Inc .(纳斯达克:NBIX)今天宣布提交新药申请(NDA)向美国食品和药物管理局(FDA)对elagolix试验性,口服促性腺激素释放激素(GnRH)拮抗剂,重管理月经出血(HMB)与子宫肌瘤的女性联系在一起。

< ![CDATA[艾希莉·提斯黛尔加入了艾尔建的女性知道运动]]>

星期一,2019年7月29日07:30:00 EST

<位置idsrc = " xmltag.org " value = "陆/ ie . .dublin">DUBLIN, July 29, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today a partnership with actress, musician and producer Ashley Tisdale, bringing awareness to the digital-first 'Women Who Know' campaign that inspires women who are writing their own futures to take charge of their decisions when it comes to reproductive health and contraceptive options.

< ![CDATA [AbbVie呈现积极的三期数据证明临床实验Elagolix减少沉重的月经出血子宫肌瘤的妇女在2018年AAGL全球国会]]>

结婚,2018年11月14日17:11:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 11月。2018 AbbVie从(NYSE: ABBV),全球生物制药公司研究,与神经内分泌的生物科学合作,Inc .(纳斯达克:NBIX),今天首次提出了额外的两个复制关键的3期临床试验的结果(ELARIS UF-1 (m12 - 815)和ELARIS UF-2& # 160; (m12 - 817)的有效性和安全性评估elagolix女性子宫肌瘤强生的# 160;这些结果47 <一口> th < /一口>美国妇科Laparoscopists协会(AAGL)全球微创妇科国会在<跨类= " xn-location " >拉斯维加斯,NV。

< ![CDATA [AbbVie宣布正背线从3级扩展研究结果评估临床实验Elagolix女性子宫肌瘤]]>

结婚,2018年8月22日08:08:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 8月。2018 ,从AbbVie (NYSE: ABBV),全球生物制药公司研究,与神经内分泌的生物科学合作,Inc .(纳斯达克:NBIX)宣布,第三阶段的结果ELARIS UF-EXTEND扩展(mi2 - 816)的研究显示,在12月,elagolix(300毫克每日两次),结合低剂量激素(添加)疗法(雌二醇1.0毫克/醋酸炔诺酮0.5毫克),减少重月经出血与87.9%的女性子宫肌瘤临床反应。

< ![CDATA [AbbVie收到美国FDA批准ORILISSA™(elagolix)管理中度到重度的疼痛与子宫内膜异位症有关]]>

星期二,2018年7月24日08:07:00 EST

北芝加哥,病了。, July 24, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA™ (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.^1,2The FDA approved ORILISSA under priority review. ORILISSA represents the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade and is expected to be available in U.S. retail pharmacies in early August 2018.

< ![CDATA [AbbVie Elagolix提出新的研究数据在2018年的美国妇产科医师学会(妇产科)年度会议]]>

星期五,2018年4月27日08:04:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 4月27日,2018年 & # 160;从AbbVie (NYSE: ABBV),全球生物制药公司研究,与神经内分泌的生物科学合作,Inc .(纳斯达克:NBIX)今天宣布,数据& # 160;elagolix,一个临床实验的,口头管理促性腺激素释放激素(GnRH)受体拮抗剂,将会在2018年美国妇产科医生大学的校长(妇产科)临床和科学年会在<跨类= " xn-location " >奥斯汀TX。

< ![CDATA [AbbVie和神经内分泌的生物科学宣布PDUFA目标日期2018年第三季度的Elagolix Endometriosis-Associated疼痛]]>

星期二,2018年4月10 08:04:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 4月10日2018年 AbbVie从(NYSE: ABBV),一个全球性的研究和开发与神经内分泌的生物科学生物制药公司合作,公司(纳斯达克:N狗万正网地址BIX),宣布通知由美国食品和药物管理局(FDA),它需要长时间回顾附加信息提供的关于肝功能测试的结果AbbVie连接的新药申请(NDA) elagolix endometriosis-associated痛苦。处方药用户费用法案(PDUFA)日期2018年第三季度已经延长三个月。

< ![CDATA [AbbVie宣布正背线从第二阶段3研究结果评估临床实验Elagolix女性子宫肌瘤]]>

星期二,2018年3月13日08:03:00 EST

北芝加哥,病了。, March 13, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint. Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg / norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding with 76.2 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (10.1 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.02) at month six.¹

< ![CDATA [AbbVie宣布正背线从3级研究结果评估临床实验Elagolix女性子宫肌瘤]]>

结婚,2018年2月21日08:02:00 EST

北芝加哥,病了。, 2月。21, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced that the Phase 3 ELARIS UF-I study (M12-815) of elagolix met its primary endpoint. Results from the first of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone (add-back) therapy, reduced heavy menstrual bleeding with 68.5 percent (p<0.001) of women with uterine fibroids achieving clinical response compared to placebo (8.7 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six. The study also met all ranked secondary endpoints (p<0.001) at month six.⁴

< ![CDATA [AbbVie宣布正阶段3扩展研究子宫内膜异位症的临床实验的口服治疗Elagolix数据管理相关的疼痛]]>

结婚,2017年11月01 12:11:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 11月。1, 2017 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced detailed results from two replicate Phase 3 extension studies evaluating the long-term efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being evaluated for the management of endometriosis with associated pain. In the extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain and non-menstrual pelvic pain in women through the 12-month treatment period. The safety and tolerability of elagolix was consistent with the anticipated effects of reduced estradiol levels and no new safety concerns were identified with elagolix use for the 12-month treatment period¹. These results, and other additional abstracts, were presented at the American Society for Reproductive Medicine Scientific Congress & Expo (ASRM) in San Antonio.

< ![CDATA [AbbVie收到美国FDA优先审查临床实验的口服治疗Elagolix子宫内膜异位症相关的疼痛管理]]>

星期五,2017年10月27日07:10:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 10月。2017 AbbVie从(NYSE: ABBV),基于研究和开发与神经内分泌的生物科学全球生物制药公司合作,公司狗万正网地址(纳斯达克:NBIX)今天宣布,美国食品和药物管理局(FDA)批准为elagolix优先审查,一个临床实验的,口头管理促性腺激素释放激素(GnRH)拮抗剂,被调查管理的子宫内膜异位疼痛有关。,FDA资助优先审查药品提供了重大改进,它决定了有潜力的治疗安全性和有效性的严重疾病<一口> 1 < /一口>。用户收费行为,AbbVie预计处方药(PDUFA)日期为FDA最迟将在2018年第二季度完成调查。

< ![CDATA [AbbVie提交新药申请美国食品及药物管理局临床实验的口头Elagolix治疗子宫内膜异位症相关疼痛的管理]]>

结婚,06年9月2017 08:09:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 9月。2017 ,从AbbVie (NYSE: ABBV),基于研究和开发与神经内分泌的生物科学全球生物制药公司合作,公司(纳斯达狗万正网地址克:NBIX),宣布它已经提交新药申请(NDA)为elagolix美国食品和药物管理局,一个临床实验的,口头管理促性腺激素释放激素(GnRH)拮抗剂,为子宫内膜异位的管理与评估相关疼痛。,在两个复制三期临床研究,elagolix展示优势与安慰剂相比减少三种类型的endometriosis-associated疼痛mdash;每日月经骨盆疼痛,non-menstrual盆腔疼痛和性交疼痛。

< ![CDATA [AbbVie提出关键的三期临床实验的数据处理Elagolix世界大会的子宫内膜异位症]]>

2017年5月17日结婚12:05:00 EST

北芝加哥,病了。, May 17, 2017 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data from two replicate Phase 3 studies evaluating the efficacy and safety of elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, in premenopausal women with endometriosis, will be presented at the 13th World Congress on Endometriosis in Vancouver, Canada. New data highlighting the effects of two different elagolix doses and dosing regimens on ovarian sex hormones and ovulation will also be presented.

< ![CDATA [AbbVie宣布正相2 b数据证明临床实验医学Elagolix显著降低重女性月经出血与子宫肌瘤))>

星期五,07年4月2017 08:04:00 EST

北芝加哥,病了。、<跨类= " xn-chron " > 4月7日,2017年 AbbVie从(NYSE: ABBV),与神经内分泌的生物科学全球生物制药公司合作,公司(纳斯达克:NBIX)今天宣布详细2 b期临床试验结果的有效性和安全性评估elagolix单独或结合再添加治疗(雌二醇/醋酸炔诺酮)与安慰剂相比。数据表明elagolix,有或没有再添加疗法,遇到的主要疗效端点减少沉重的月经出血与安慰剂相比(术中,0.001)。这些结果共享第一次口头报告在第三国会子宫内膜异位和子宫疾病的社会(SEUD) <跨类= " xn-location " >新加坡。